Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Accro Bioscience Announces Inclusion of AC-101 tablets in the NMPA CDE's "Caring Plan ...

14 September 2026 · By · Wire by Fusion42

Published

14 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

China

◆ Source

Read at wboc.com →

◆ Verified

Fusion42 · 14 September 2026 · Fusion42 review

Accro Bioscience's AC-101 tablets have been included in the Chinese National Medical Products Administration Center for Drug Evaluation's (NMPA CDE) "Caring Plan-Extension" pilot program, aimed to accelerate the development and approval of rare disease drugs in China.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Chinese biotech founders developing treatments for rare diseases now face a faster approval path that could cut years off market entry. You need to engage regulatory experts to align with the NMPA’s new rare disease pilot program and access this emerging opportunity.

◆ Coverage

1 source · 14 Sep 2026

◆ Related on Wire

◆ Topics

Biotechchina-regulationrare-diseasedrug-approvalbiotechnmpaclinical-trials